Volume | 2,456,098 |
|
|||||
News | - | ||||||
Day High | 0.4822 | Low High |
|||||
Day Low | 0.4501 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
23andMe Holding Company | ME | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4563 | 0.4501 | 0.4822 | 0.459 | 0.4671 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,108 | 2,456,098 | $ 0.4671001 | $ 1,147,244 | - | 0.35 - 2.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:25:13 | formt | 100 | $ 0.469 | USD |
23andMe Holding Company Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
222.14M | 482.92M | - | 299.49M | -311.66M | -0.65 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
23andMe News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ME Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4708 | 0.619 | 0.43 | 0.4964043 | 18,064,128 | -0.0018 | -0.38% |
1 Month | 0.5224 | 0.619 | 0.35 | 0.4831575 | 7,622,068 | -0.0534 | -10.22% |
3 Months | 0.7439 | 0.826 | 0.35 | 0.5667979 | 7,810,345 | -0.2749 | -36.95% |
6 Months | 0.7808 | 1.02 | 0.35 | 0.6776928 | 6,268,423 | -0.3118 | -39.93% |
1 Year | 2.00 | 2.21 | 0.35 | 0.9169157 | 4,445,806 | -1.53 | -76.55% |
3 Years | 11.00 | 13.68 | 0.35 | 3.02 | 3,457,085 | -10.53 | -95.74% |
5 Years | 11.00 | 13.68 | 0.35 | 3.02 | 3,457,085 | -10.53 | -95.74% |
23andMe Description
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates. |